{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T06:20:00Z","timestamp":1762928400518,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":30,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493933884"},{"type":"electronic","value":"9781493933891"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3389-1_22","type":"book-chapter","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T11:22:46Z","timestamp":1460632966000},"page":"313-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Alphavirus-Based Vaccines"],"prefix":"10.1007","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"22_CR1","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1586\/erv.12.38","volume":"11","author":"I Delrue","year":"2012","unstructured":"Delrue I, Verzele D, Madder A, Nauwynck HJ (2012) Inactivated virus vaccines: from chemistry to prophylaxis: merits, risks and challenges. Expert Rev Vaccines 11:695\u2013719","journal-title":"Expert Rev Vaccines"},{"key":"22_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s12250-012-3241-1","volume":"27","author":"MP Deng","year":"2012","unstructured":"Deng MP, Hu ZH, Wang HL, Deng F (2012) Developments of subunit and VLP vaccines against influenza A virus. Virol Sin 27:145\u2013153","journal-title":"Virol Sin"},{"key":"22_CR3","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/nbt1291-1356","volume":"9","author":"P Liljestrom","year":"1991","unstructured":"Liljestrom P, Garoff H (1991) A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) 9:1356\u20131361","journal-title":"Biotechnology (N Y)"},{"key":"22_CR4","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.2922607","volume":"243","author":"C Xiong","year":"1989","unstructured":"Xiong C, Levis R, Shen P, Schlesinger S, Rice CM, Huang HV (1989) Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243:1188\u20131191","journal-title":"Science"},{"key":"22_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","volume":"171","author":"NL Davies","year":"1989","unstructured":"Davies NL, Brown KW, Johnston RE (1989) In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 171:189\u2013204","journal-title":"Virology"},{"key":"22_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14760584.2.3.445","volume":"2","author":"K Lundstrom","year":"2003","unstructured":"Lundstrom K (2003) Alphavirus vectors for vaccine production and gene therapy. Expert Rev Vaccines 2:447\u2013459","journal-title":"Expert Rev Vaccines"},{"key":"22_CR7","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.3390\/v6062392","volume":"6","author":"K Lundstrom","year":"2014","unstructured":"Lundstrom K (2014) Alphavirus-based vaccines. Viruses 6:2392\u20132415","journal-title":"Viruses"},{"key":"22_CR8","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1089\/aid.1998.14.1369","volume":"14","author":"D Brand","year":"2000","unstructured":"Brand D, Lemiale F, Turbica I, Buzelay L, Brunet S, Barin F (2000) Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res Hum Retroviruses 14:1369\u20131377","journal-title":"AIDS Res Hum Retroviruses"},{"key":"22_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/IAI.71.1.575-579.2003","volume":"71","author":"JR Kirman","year":"2003","unstructured":"Kirman JR, Turon T, Su H, Li A, Kraus C, Polo JM et al (2003) Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun 71:575\u2013579","journal-title":"Infect Immun"},{"key":"22_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0166-0934(99)00009-9","volume":"79","author":"A Giraud","year":"1999","unstructured":"Giraud A, Ataman-Onal Y, Battail N, Piga N, Brand D, Mandrand B et al (1999) Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J Virol Methods 79:75\u201384","journal-title":"J Virol Methods"},{"key":"22_CR11","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1128\/JVI.71.4.3031-3038.1997","volume":"71","author":"IJ Caley","year":"1997","unstructured":"Caley IJ, Betts MR, Irlbeck DM, Davis NL, Swanstrom R, Frelinger JA et al (1997) Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 71:3031\u20133038","journal-title":"J Virol"},{"key":"22_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0264-410X(00)00113-4","volume":"19","author":"P Pushko","year":"2000","unstructured":"Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A et al (2000) Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19:142\u2013153","journal-title":"Vaccine"},{"key":"22_CR13","doi-asserted-by":"publisher","first-page":"7451","DOI":"10.1016\/j.vaccine.2009.05.014","volume":"27","author":"SG Yang","year":"2009","unstructured":"Yang SG, Wo JE, Li MW, Mi FF, Yu CB, Lv GL et al (2009) Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1). Vaccine 27:7451\u20137458","journal-title":"Vaccine"},{"key":"22_CR14","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1128\/JVI.03361-12","volume":"87","author":"AS Herbert","year":"2013","unstructured":"Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE et al (2013) Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with Ebolavirus. J Virol 87:4952\u20134964","journal-title":"J Virol"},{"key":"22_CR15","doi-asserted-by":"publisher","first-page":"6604","DOI":"10.1016\/j.vaccine.2007.06.058","volume":"25","author":"TP Moran","year":"2007","unstructured":"Moran TP, Burgents JE, Long B, Ferrer I, Jaffee EM, Tisch RM et al (2007) Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 25:6604\u20136612","journal-title":"Vaccine"},{"key":"22_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.cgt.7700300","volume":"8","author":"LB Lachman","year":"2001","unstructured":"Lachman LB, Rao XM, Kremer RH, Ozpolat B, Kiriakova G, Price JE (2001) DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther 8:259\u2013268","journal-title":"Cancer Gene Ther"},{"key":"22_CR17","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/10548","volume":"5","author":"H Ying","year":"1999","unstructured":"Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM et al (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823\u2013827","journal-title":"Nat Med"},{"key":"22_CR18","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1016\/S0264-410X(00)00042-6","volume":"18","author":"MK Hart","year":"2000","unstructured":"Hart MK, Caswell-Stephan K, Bakken R, Tammariello R, Pratt W, Davis N et al (2000) Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 18:3067\u20133075","journal-title":"Vaccine"},{"key":"22_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000928","volume":"5","author":"K Mallilankaraman","year":"2011","unstructured":"Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU et al (2011) A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 5, e928","journal-title":"PLoS Negl Trop Dis"},{"key":"22_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.4269\/ajtmh.2000.62.681","volume":"62","author":"R Edelman","year":"2000","unstructured":"Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA (2000) Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62:681\u2013685","journal-title":"Am J Trop Med Hyg"},{"key":"22_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.vaccine.2009.09.135","volume":"28","author":"DI Bernstein","year":"2009","unstructured":"Bernstein DI, Reap EA, Katen K, Watson A, Smith K, Norberg P et al (2009) Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28:484\u2013493","journal-title":"Vaccine"},{"key":"22_CR22","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1172\/JCI42672","volume":"120","author":"MA Morse","year":"2010","unstructured":"Morse MA, Hobeika AC, Osada T, Berglund P, Hubby B, Negri S et al (2010) An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 120:3234\u20133241","journal-title":"J Clin Invest"},{"key":"22_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.vaccine.2012.11.096","volume":"31","author":"SF Slovin","year":"2013","unstructured":"Slovin SF, Kehoe M, Durso R, Fernandez C, Olson W, Gao JP et al (2013) A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 31:943\u2013949","journal-title":"Vaccine"},{"key":"22_CR24","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nbt1194-1127","volume":"12","author":"EM Sj\u00f6berg","year":"1994","unstructured":"Sj\u00f6berg EM, Suomalainen M, Garoff H (1994) A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology 12:1127\u20131131","journal-title":"Biotechnology"},{"key":"22_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S1525-0016(02)00056-4","volume":"7","author":"K Lundstrom","year":"2003","unstructured":"Lundstrom K, Abenavoli A, Malgaroli A, Ehrengruber MU (2003) Novel Semliki Forest virus vectors with reduced toxicity and temperature-sensitivity for long-term enhancement of transgene expression. Mol Ther 7:202\u2013209","journal-title":"Mol Ther"},{"key":"22_CR26","first-page":"916","volume":"11","author":"P Berglund","year":"1993","unstructured":"Berglund P, Sj\u00f6berg M, Garoff H, Atkins GJ, Sheahan BJ, Liljestrom P (1993) Semliki forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology 11:916\u2013920","journal-title":"Biotechnology"},{"key":"22_CR27","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4049\/jimmunol.156.1.238","volume":"156","author":"KR Irvine","year":"1996","unstructured":"Irvine KR, Rao JB, Rosenberg SA, Restifo NP (1996) Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 156:238\u2013245","journal-title":"J Immunol"},{"key":"22_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012670","volume":"5","author":"F Avogadri","year":"2010","unstructured":"Avogadri F, Merghoub T, Maughan MF, Hirschhorn-Cymerman D et al (2010) Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 5, e12670","journal-title":"PLoS One"},{"key":"22_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm813","volume":"5","author":"WW Reitner","year":"2003","unstructured":"Reitner WW, Hwang NL, de Veer MJ, Zhou A, Silverman RH, Williams BRG et al (2003) Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 5:33\u201339","journal-title":"Nat Med"},{"key":"22_CR30","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1006\/viro.1998.9357","volume":"250","author":"G Colombage","year":"1998","unstructured":"Colombage G, Hall R, Pavy M, Lobigs M (1998) DNA-based and alphavirus-vectored immunization with PrM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250:151\u2013163","journal-title":"Virology"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3389-1_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T16:54:33Z","timestamp":1692291273000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3389-1_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933884","9781493933891"],"references-count":30,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3389-1_22","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"14 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}